Watch tender results after Nov 6 expiration — full participation would eliminate 12.3M share overhang, a clear positive for the capital structure. Partial tenders still reduces dilution but leaves residual warrants remain outstanding.
Price Chart
Executive Summary
Jasper Therapeutics commenced a tender offer to repurchase up to all 12,345,707 outstanding warrants (issued in Sep 2025) at $0.324 per warrant in cash, for a total of ~$4.0 million if fully tendered. The offer aims to reduce potential dilution from the warrants, which have a $2.92 exercise price, and runs through November 6, 2026.
Key Facts
- Offer to repurchase all outstanding warrants at $0.324 per warrant in cash
- 12,345,707 warrants outstanding as of October 6, 2026
- Each warrant exercisable for one share of common stock at $2.92 per share
- Maximum cash outlay ~$4.0 million if all warrants tendered, funded from cash on hand
- Offer open until 11:59 p.m. ET on November 6, 2026
- Warrants not tendered remain outstanding and expire March 18, 2030
- No minimum tender minimum required; no dealer manager, information agent, or depositary hired
Financial Impact
Up to ~$4.0 million cash outlay to eliminate 12.3M shares of potential dilution; warrants represent ~12.3M shares at $2.92 strike vs. current price
Risk Factors
- Warrant holders may not tender; some holders may hold out, leaving residual dilution overhang
- Cash outlay of ~$4.0M reduces cash runway for a clinical-stage biotech
- No minimum tender minimum — if few warrants tendered, the offer's benefit is limited
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-107402 |
| Document: ea030792501ex99-1.htm | 0001213900-26-107402 |
| Document: 0001213900-26-107402-index-headers.html | 0001213900-26-107402 |
| Document: 0001213900-26-107402-index.html | 0001213900-26-107402 |
| Document: 0001213900-26-107402.txt | 0001213900-26-107402 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC TO-I/A | $0.5100 | awaiting T+5 | — | $0.5050 (−0.98%) |
Oct 20, 2026 6d ago | DEF 14A | $0.4999 | awaiting T+5 | — | $0.5050 (+1.02%) |
Oct 15, 2026 11d ago | 8-K | $0.5321 $0.4956 | ▼ −6.86% | ▼ −5.85% | $0.5050 (−5.09%) |
Oct 15, 2026 11d ago | Press Release | $0.5320 $0.4960 | ▲ +6.77% | ▲ +5.75% | $0.5050 (+5.08%) |
Oct 14, 2026 12d ago | S-3 | $0.5321 $0.4956 | ▲ +6.86% | ▲ +5.85% | $0.5050 (+5.09%) |
Oct 7, 2026 19d ago | 8-K | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5050 (−11.36%) |
Oct 7, 2026 19d ago | SC TO-I | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5050 (−11.36%) |
Sep 24, 2026 4w ago | 25-NSE | $0.6091 $0.5652 | ▲ +7.21% | ▲ +6.99% | $0.5050 (+17.09%) |
Aug 14, 2026 10w ago | Press Release | $0.7901 $0.7160 | ▼ −9.38% | ▼ −8.01% | $0.5050 (−36.08%) |
Jul 31, 2026 12w ago | 8-K | $0.6300 $0.7095 | ▲ +12.62% | ▲ +9.11% | $0.5050 (−19.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers